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Abstract – Apolipoprotein E displays polymorphism with three common alleles, e2, e3, and e4. The aim of this research was 
to determine apoE gene polymorphism in a group of healthy patients and a group of patients with CHD, and to reveal the 
relation between anthropometric and biochemical parameters and the apoE genotype. In CHD group significantly higher 
values of blood pressure, waist circumference, BMI and fat %, triglycerides, insulin (HOMA IR) and CRP were found. A 
statistically significant higher presence of the e3e4 genotype and e4 allele was detected in the CHD group. Statistically 
significant differences between waist circumference, BMI, insulin and HOMA IR were found between subjects with e3e3 
and e3e4 genotypes.
Key words: Apolipoprotein E, coronary heart disease, Serbia
UDC 577.112.85:616(497.11)
INTRODUCTION
Coronary heart disease (CHD) is a complex multi-
factorial state. Different exogenous and endogenous 
factors influence the development of CHD. Athero-
sclerosis is a major change in the development of 
CHD. Major attention in recent cardiovascular dis-
ease research has been given to understanding the 
molecular basis of atherosclerosis (Greenow et al., 
2005). Apolipoprotein E (ApoE) is a structural com-
ponent of both chylomicrons and very low-density 
lipoprotein  (LDL)  remnants.  Apolipoprotein  E  is 
thought to play a central role in atherosclerosis by 
participating in overall plasma cholesterol homeos-
tasis, mainly via the regulation of the hepatic uptake 
of remnant lipoproteins, by facilitating cholesterol 
efflux from macrophage foam cells within athero-
sclerotic  lesions,  and  by  modifying  inflammatory 
responses (Dimitrios et al., 2006). The ApoE protein 
also carries out additional functions such as the pre-
vention of platelet aggregation and the inhibition of 
the proliferation of T-lymphocytes and endothelial 
cells. ApoE therefore plays a key protective role in 
atherosclerosis (Rall and Mahley, 1992). In addition, 
ApoE participates in neuronal repair in the central 
nervous system (Weisgraber and Mahley, 1996; Al-
Khedhairy, 2004).
The single polypeptide chain of ApoE (299 resi-
dues, 34.2 kDa molecular mass) contains two inde-
pendently folded domains that are approximated by 
two  thrombolytic  fragments  (residues  1–191  and 90 I. DJAN ET AL.
216–299), which are involved in different functions 
of the protein (Weisgraber, 1994; Segall et al., 2002). 
The 22 kDa N-terminal fragment contains the LDLR 
binding domain (residues 136–150) and the C-ter-
minal 10 kDa fragment represents the major lipid-
binding region.
Apolipoprotein  E  displays  genetic  polymor-
phism with three common alleles, e2, e3, and e4, 
in a single-gene locus on the chromosome 19q13.2 
that gives rise to 3 homozygous (apoE2/2, apoE3/3, 
apoE4/4) and 3 heterozygous genotypes (apoE2/3, 
apoE2/4, apoE3/4) (Davignon et al., 1988; Dimi-
trios et al., 2006). A higher number of polymor-
phisms in the apoE gene have been identified, and 
the functional consequences of these changes along 
with their association with cardiovascular disease 
have been investigated. ApoE is a polymorphic pro-
tein with three common isoforms and more than 
20 rare variants (Rall and Mahley, 1992). ApoE3 
(Cys112,  Arg158)  is  considered  to  be  the  parent 
form  and  ApoE4  (Arg112,  Arg158)  and  ApoE2 
(Cys112, Cys158) are variants. This polymorphism 
was found to be relevant for the ApoE plasma level, 
the receptor binding affinity of ApoE, plasma lipid 
and lipoprotein concentrations, and CAD (Koch et 
al., 2004).
Evidence exists to suggest that the variability of 
apoE has differential effects on the atheroprotective 
potential attributed to ApoE. The apoE allele e4 is as-
sociated with increased LDL cholesterol levels and 
decreased ApoE plasma concentrations (Davignon 
et al., 1988; Stokic et al., 2008). Conversely, the e2 
allele is associated with reduced LDL cholesterol lev-
els and higher ApoE plasma concentrations. Among 
patients with CAD, the e4 allele was related to more 
severe disease and the e2 allele to less severe dis-
ease (Koch et al., 2004). The presence of the e4 al-
lele has been associated with increased death rates 
in patients with CAD. The cardiovascular risk attrib-
uted to the e4 allele may be related, at least in part, 
to a lower antioxidant activity of the ApoE4 isoform 
(112Arg/158Arg)  compared  to  that  of  the  ApoE2 
isoform  (112Cys/158Cys)  or  the  ApoE3  isoform 
(112Cys/ 158Arg) (Koch et al., 2004). Another SNP 
of apoE, –219G/T, located in the promoter of apoE, 
was reported to be significantly associated with apoE 
promoter activity, ApoE plasma concentration, and 
CAD (Lambert et al., 2000; Hirashiki et al., 2003).
Allelic frequencies differ in different populations 
(Eichner et al., 2002). Furthermore, wide range pop-
ulation studies have indicated interethnic variations 
in apoE polymorphism. At a global level, higher fre-
quencies of the e2 allele were observed in Africa and 
Oceania (0.099 and 0.083 and 0.111 and 0.052, re-
spectively). Similarly, e4 allele averages were higher 
in Oceania (0.221 and 0.149) and Africa (0.209 and 
0.090), while Indian and Asian populations showed 
the highest frequencies of e3 allele. The coefficient of 
gene differentiation was found to be highest in South 
America (9.6%), although the highest genetic diver-
sity  was  observed  in  Oceania  (48.7%)  and  Africa 
(46.3%). ApoE e2 revealed a statistically significant 
decreasing cline towards the north in Asia, which is 
not compatible with the coronary heart disease sta-
tistics in this continent. ApoE e4 showed a signifi-
cant increasing cline in North European populations 
(Singh et al., 2006). It was shown that allele e4 was 
present in higher frequency in the Swedish popula-
tion (20.3%), compared to other European popula-
tions (Eggertsen et al., 1993). In the healthy Serbian 
population the allele e3 was present with 73.6% fre-
quency, and e2 and e4 with 14.9% and 11.5%, respec-
tively (Stanković et al., 1999).
The  investigation  of  apoE  polymorphism  in 
CHD patients from Serbia has not been done be-
fore. According to the MONICA study (Monitoring 
Trends and Determinants in Cardiovascular Diseas-
es), the population of Vojvodina (northern Serbian 
Province) was in the worst position from the start of 
study in frequency of CHD. In the majority of other 
research centers included in the study, the research 
center in Vojvodina registered an increase of mor-
tality rates due to CHD. The mean total cholesterol 
level registered in the beginning was 36th place for 
men and 31st for women (out of 38). At the end of 
the study the mean total cholesterol level increased 
and rose to 2nd place for men and 3rd for women 
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The majority of studies dealing with the associa-
tion of the apoE genotype and coronary heart disease 
development were performed either in general pop-
ulations (Eggersten et al., 1993; Lahoz et al., 2001; 
Singh et al., 2006) or in the elderly (Al- Khedhairy, 
2004; Stengård et al., 1999). Since inheritance can 
be considered to be an unchangeable risk factor, it 
seemed interesting to investigate the influence of the 
apoE genotype to the development and occurrence 
of CHD in the younger population.
Therefore, the aim of this research was to deter-
mine apoE gene polymorphism in a healthy control 
group and a group of patients with CHD, both com-
prising men from 18 to 45 years of age, and to reveal 
the relations between different anthropometric and 
biochemical parameters and the apoE genotype.
MATERIALS AND METHODS
Sixty individuals, aged from 18 to 45, from the north-
ern Serbian province of Vojvodina were involved in 
the study. The control group consisted of 30 unre-
lated healthy men. In group of patients with CHD, 
30 unrelated men were included who had had no 
hypolipidemic treatment. These patients underwent 
complete  medical  examination  and  CHD  was  de-
termined by coronarography or MDCT (multi-slice 
detector  computed  tomography)  coronarography. 
Cases  with  a  previous  myocardial  infarction  were 
included in this group. The study was performed ac-
cording to the Declaration of Helsinki and informed 
consent was obtained from all participants.
Anthropometric  measurements  (body  weight, 
body height and waist circumference), body fat mass 
estimation  and  cardiovascular  risk  factors  assess-
ment (systolic and diastolic pressure, fasting serum 
lipids levels, fasting serum glucose levels, insuline-
mia, C-reactive protein) were done. With the sub-
jects wearing light indoor clothes and no shoes body 
weight (BW) and body height (BH) were measured 
using a calibrated beam-type balance to the nearest 
0.1 kg and a Harpenden anthropometer to the near-
est 0.1 cm, respectively, and body mass index (BMI) 
was  calculated  [BMI  =  BW/BH2  (kg/m2)].  Waist 
circumference was measured using flexible tape to 
the nearest 0.1 cm at the level midway between the 
lowest point on the rib margin and the highest point 
on the iliac crest. Body fat mass was assessed with 
the bioelectrical impedance method using a Tanita 
TBF-310 Body Composition Analyzer (Tanita Cor-
poration, Tokyo, Japan). Systolic (SBP) and diastolic 
(DBP) blood pressure were measured in the fasted 
state, early in the morning, using sphygmomanom-
eter by Riva-Rocci, in sitting position after a 10-15 
min rest period. As the most valid value, the mean of 
three measurements was taken. Total cholesterol and 
triglycerides were determined using the commercial 
kit Boehringer Manheim GmbH. HDL-cholesterol 
was  estimated  using  the  method  of  precipitation 
with Na-phosphorvolframate, while LDL-cholester-
ol was calculated using the formula by Friedewald 
et al. (1972). Fasting plasma glucose was measured 
using  the  Dialab  glucose  GOD-PAP  method.  All 
blood samples were drawn after an overnight 12-h 
fast. Estimation of insulin resistance was performed 
by HOMA IR (homeostasis model assessment of in-
sulin resistance) according to the formula (glucose 
x insulin)/22.5 (Matthews et al., 1985). In order to 
ensure accuracy of measurement, subjects were told 
not to eat or drink within 4 h of the test, not to exer-
cise within 12 h of the test, to urinate within 30 min 
of the test and not to consume alcohol within 48 h of 
the test.
DNA was extracted from blood by standard pro-
cedures utilizing the QIAGENE kit. Primers were de-
signed to amplify the coding sequence of the fourth 
exon of the apoE gene. The following primers were 
used: F4 (5’ CTA CAG AAT TCG CCC CGG CCT 
GGT ACA C 3’) and F6 (5’ TAA GCT TGG CAC 
GGC TGT CCA AGG A 3’). PCR amplification was 
done according to the modified method of Hixon 
and Vernier (1990). A sample of 100 ng of genomic 
DNA was used as a template in a 25 μL reaction solu-
tion with 0,4µM each primer, 200µM dNTPs (dATP, 
dTTP, dCTP, dGTP), 1x Buffer, 1,25U Taq polymer-
ase, 10% DMSO and 2,5 mM MgCl2. Genomic DNA 
was amplified for 30 cycles. Each cycle consisted of 1 
min at 95°C, 1 min at 60°C and 1 min at 72°C. PCR 
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h at 37oC. The fragments obtained were separated by 
electrophoresis on a 4% agarose gel in TAE buffer, 
and  visualized  by  ethidium  bromide  fluorescence. 
The genotype of each person was determined from 
the RFLP-PCR profile.
All continuous variables are expressed as means 
± standard deviation (SD). Genotype and allele fre-
quencies were obtained by direct count. Student’s t 
test, Principle Coordinate Analysis and χ² test were 
used in STATISTICA, version 8.0. (2008). Student’s 
t test was used for testing differences between the 
means of anthropometric and biochemical param-
eters of the two groups. PCO analysis was applied 
in order to determine the parameters distinguishing 
the two analyzed groups. The differences in genotype 
and  allelic  frequencies  between  the  two  analyzed 
groups were determined using the χ² test. Probability 
values of less than 0.05 were regarded as statistically 
significant.
RESULTS
Differences in the average values of measured an-
thropometric and biochemical parameters between 
the group with CHD and control group were tested 
and only significant differences are presented in Ta-
ble 1. In the CHD group, the apoE genotype was suc-
cessfully determined for all subjects. In the control 
group, the apoE genotype could not be determined 
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for 5 of the subjects, even though the analysis was 
repeated. ApoE gene amplification was unsuccess-
ful for 2 subjects, and genotype determination could 
not be performed for 3 subjects. Statistical analysis 
showed significant differences in genotype distribu-
tion between the two groups (Tab. 1). A statistically 
significant higher presence of the e3e4 genotype was 
detected in the CHD group. Allele distribution anal-
ysis revealed differences in allelic frequencies as well 
(Tab. 1). A significantly higher frequency of the allele 
e4 was found in the CHD group (p=0.019).
PCO  analysis  defined  the  parameters  distin-
guishing between the CHD and control group in two 
dimensions and these are: waist circumference, BMI, 
fat %, index of atherosclerosis, insulin and HOMA 
IR (Fig. 1.).
In  both  groups  five  genotypes  were  detected. 
Genotypes e2e4, e4e4 and e2e3 were found in only 
Table 1. Differences in anthropometric and biochemical parameters and in allelic and genotype distribution between CHD and control 
group. For each continuous variable the results are presented as mean ±SD, median and range.
Parameter CHD Control p
Systolic pressure** (mmHg)
138.2±9.7 125.8±8.9 0.00001
140 125
110 – 160 110 – 140
Diastolic pressure* (mmHg)
89.5±9.0 84±7.3 0.017
90 80
70 – 100 70 – 100
waist circumference (cm)**
105.2±9.1 96.5±8.9 0.0008
106 96
80 – 123 80 – 119
BMI (kg/m2)*
29.3±2.8 27.3±3.6 0.032
29.2 27
21.5 – 36.5 22.5 – 36.3
Fat %*
25.9±3.8 21.1±5.2 0.0002
25.5 20.6
14.9 – 36.5 12.5 – 30.4
Insulin (μlU/ml)**
30.1±26.5 9.5±4.2 0.0003
21.5 9
2.11 – 103 3.4 – 21.1
HOMA IR **
6.5±5.8 2.1±1.1 0.0004
4.42 2
0.43 – 22.37 0.7 – 5.06
CRP (U/ml)**
5.1±5.3 1.5±2 0.003
3.95 0.6
0.36 - 31 0.1 – 8.8
Genotype distribution
e3e3
e3e4
e2e4
e4e4
e2e3
16(53.33%)
13(43.33%)
1(3.34%)
0
0
19 (76%)
4 (16%)
0
1 (4%)
1 (4%)
0.038*
Allele distribution
e3
e4
e2
45 (75%)
14(23.33%)
1 (1.67%)
43 (86%)
6 (12%)
1 (2%)
0.011*
* p<0.05; **p<0.01
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one person each. The remaining 52 subjects with e3e3 
and e3e4 genotypes were divided into two groups ac-
cording to their genotype, and regardless of their be-
longing to the CHD or control group. Average values 
of anthropometric and biochemical parameters were 
tested for differences and significant results are pre-
sented in Table 2.
PCO analysis in two dimensions defined waist 
circumference, BMI, fat %, index of atherosclerosis 
(IA) (LDL/HDL), insulin and HOMA IR as factors 
distinguishing the e3e3 and e3e4 groups (Fig. 2).
DISCUSSION
ApoE gene polymorphism was examined in 60 sub-
jects, divided into two groups: one of 30 patients 
with CHD and the other a healthy control group. A 
detailed medical examination, with anthropometric 
and biochemical parameter measurements, was per-
formed for each person. The ApoE genotype was suc-
cessfully determined in 55 (91.7%) subjects. Unsuc-
cessful PCR amplification in 2 subjects might be due 
to a mutation in the primer binding region, and the 
unsuccessful determination of the apoE genotype in 
3 subjects might be due to a novel mutation in exon 4 
that created new restriction sites and unusual RFLP-
PCR profiles. However, these presumptions must be 
further evaluated.
In this research the apoE allelic frequencies in the 
healthy control group were: e3 - 86%, e4 - 12% and 
e2 -2%. In the CHD group the allelic distribution was 
the following: e3 - 75%, e4 - 23.33%, and e2 - 1.67%. 
Compared to previous analysis of a healthy Serbian 
population (Stanković et al., 1999), the higher fre-
quency of the e3 allele in the control group and the 
significantly higher frequency of the e4 allele in the 
CHD group compared to the control, were detected.
Our study analyzed younger men (less than 45 
years old) and during the two year period of research, 
30 patients could be included in this study (mean age 
35.2±4.5). Considering the age limitation, we found 
this number quite satisfactory. First, it was expected 
that coronary heart disease is present in lower fre-
quency in younger populations. Furthermore, some 
registered cases couldn’t be included in the research 
due  to  either  the  hypolipidemic  medication  treat-
ment they were taking in a previous time period or 
Table 2. Differences in anthropometric and biochemical parameters between e3e3 and e3e4 genotype groups. 
For each parameter the results are presented as mean ±SD, median and range.
Parameter e3e3 e3e4 p
Waist circumference (cm)* 99.1±9.9 105.5±8.8 0.028
100 106
80-118 91-123
BMI (kg/m2)* 27.9±3.08 29.7±3.2 0.048
27.8 28.4
21.5-36.3 24.5-36.5
Fat %* 23.0±5.0 25.5±4.3 0.087
24.5 25.2
12.5-30.6 16.1-36.5
Insulin (μlU/ml)** 15.7±19.3 33.3±25.0 0.007
9 23.1
2.11-103 4.72-79.9
HOMA IR ** 3.4±3.8 7.3±6.0 0.006
2 4.62
0.43-17.85 1.05-22.37
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due to the fact that some patients didn’t give signed 
informed  consent.  Nonetheless,  this  small  sample 
size revealed expected differences in several anthro-
pometric and biochemical parameters.
In the CHD group significantly higher values of 
blood pressure, waist circumference, BMI and fat %, 
as well as, levels of triglycerides, insulin (HOMA IR) 
and CRP, were found. Even though no statistically 
significant difference was found for some expected 
measurements, such as LDL cholesterol or total cho-
lesterol, PCO analysis detected the index of athero-
sclerosis (IA) as a distinguishing factor between the 
two groups. Since IA directly depends on LDL cho-
lesterol, it can be concluded that this parameter also 
differs between these groups.
Frikke-Schmidt  et  al.  (2004)  showed  signifi-
cant differences between CHD patients and healthy 
control (men and women) in total cholesterol, LDL 
cholesterol, HDL cholesterol and triglyceride levels, 
and BMI and blood pressure. In our research we con-
firmed findings for blood pressure, BMI and triglyc-
erides. McCarthy et al. (2004) also confirmed signifi-
cant differences in BMI and blood pressure between 
CHD patients and controls. Furthermore, März et al. 
(2004) detected significant differences in blood pres-
sure between patients with coronary artery disease 
Fig. 2. PCO analysis of measured parameters between e3e3 and e3e4 groups.96 I. DJAN ET AL.
and controls, and no differences in LDL cholesterol 
and HDL cholesterol, similar to our research. Also, 
Kolovou et al. (2002) did not register differences in 
cholesterol levels between CHD and control groups. 
However,  studies  in  which  significant  differences 
in cholesterol levels were reported, analyzed larger 
numbers of subjects (1309 (März et al., 2004) and 
9238 (Frikke-Schmidt et al., 2004)). Therefore it can 
be concluded that detected differences partially de-
pend on the size of the analyzed population and the 
origin of the population. In our research the Student 
t test revealed p=0.06 for testing difference in the 
LDL cholesterol level between the CHD and control 
groups, indicating that a larger number of subjects 
would lead to a statistically significant difference for 
this parameter.
As was expected, in the CHD group a statisti-
cally significant higher percentage of the e3e4 geno-
type and e4 allele was found. Other studies revealed 
a similar correlation between e4 allele presence and 
CHD. In Finnish men older than 65 a higher CHD 
mortality was found in those with an e3e4 genotype 
compared to those with an e3e3 genotype (Stengård 
et al., 1999). The Framingham Heart Study found 
that the presence of the e4 allele in men shows a 
positive  correlation  with  CHD  development,  and 
no such correlation was found in women (Lahoz et 
al., 2001). Furthermore, it was detected in the Fram-
ingham Heart Study that apoE gene polymorphism 
and CHD risk are not correlated in non-smoking 
subjects, while this relation was positive in smoking 
subjects (Talmud et al., 2005). A significant correla-
tion between the apoE gene and CHD was confirmed 
in the analysis of 111 candidate genes (McCarthy et 
al., 2004). It was also shown that allele e4 of the apoE 
gene has an additive effect in myocardial infarction 
(yamada et al., 2002). On the other hand, several 
studies did not confirm a correlation between e4 al-
lele and CHD (Kolovou et al., 2002).
Statistically significant differences in waist cir-
cumference, BMI, insulin and HOMA IR were found 
in our research between subjects with e3e3 and e3e4 
genotypes. Numerous population studies have de-
tected the effect of apoE gene polymorphism on lipid 
levels. Eggertsen et al. (1993) and Chen et al. (2003) 
showed a positive correlation between e3 and e4 al-
leles and total cholesterol level, as well as between e4 
allele and LDL cholesterol level. On the other hand, 
Guerra et al. (2003) did not find a difference in li-
pid concentration between e3e3 and e3e4 genotype 
groups. In our research the level of LDL cholesterol in 
the e3e3 genotype group was 3.0±0.8 mmol/l, and in 
the e3e4 genotype group, 3.5±1.0 mmol/l (p=0.098). 
The confidence interval in our research is quite wide 
(OR 2.23, CI 0.78 – 6.33), indicating that a total of 60 
subjects is not sufficient for detecting a difference for 
this parameter. In other studies that have found this 
difference the number of analyzed subjects was from 
250 to 10000.
As previously mentioned, the lower number of 
subjects was partially defined by the study design 
(male patients younger than 45). Since only 30 men 
could be included in the CHD group, the control 
group was created to match the CHD patients group 
(the mean age in the control group was 32.8±6.1). 
Statistical analysis showed that a difference in the 
LDL cholesterol level can be revealed with a higher 
number of patients.
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